Long-term Efficacy and Safety of Up to 108 Weeks of Ixekizumab in Pediatric Patients With Moderate to Severe Plaque Psoriasis
About 1% of children and adolescents worldwide are affected by plaque psoriasis.To evaluate the long-term efficacy and safety of ixekizumab for pediatric patients with moderate to severe psoriasis.This multicenter randomized clinical trial (IXORA-PEDS) evaluated pediatric patients with plaque psoria...
Elmentve itt :
| Szerzők: | |
|---|---|
| Dokumentumtípus: | Cikk |
| Megjelent: |
2022
|
| Sorozat: | JAMA DERMATOLOGY
158 No. 5 |
| Tárgyszavak: | |
| doi: | 10.1001/jamadermatol.2022.0655 |
| mtmt: | 33088929 |
| Online Access: | http://publicatio.bibl.u-szeged.hu/26533 |